Truist analyst Richard Newitter raised the firm’s price target on iRhythm (IRTC) to $146 from $120 and keeps a Buy rating on the shares. The firm cites the company’s revenue and EBITDA beat thanks to Zio outperformance and guidance raise on a higher U.S. growth outlook, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRTC:
- iRhythm Technologies Reports Strong Q1 2025 Growth
- Apple downgraded, Reddit upgraded: Wall Street’s top analyst calls
- iRhythm price target raised to $150 from $133 at Baird
- iRhythm price target raised to $140 from $135 at BTIG
- Irhythm Technologies: Strong Performance and Growth Potential Justify Buy Rating